Identification and treatment of persons with latent Mycobacterium tuberculosis infection is an essential component of tuberculosis control in low tuberculosis-incidence countries [1] . Cancer has been a well-recognized risk factor for developing active M. tuberculosis infection since the 1970s; however, the absolute and relative risk for different cancer types and the change in risk over time has not been well defined. US and Canadian guidelines identify immunosuppression due to human immunodeficiency virus, organ transplant, prolonged therapy with corticosteroids, tumor necrosis factor-alpha inhibitors, hematologic malignancies, and head and neck cancers as important risk factors for developing active tuberculosis [2, 3] . The magnitude of risk due to hematologic malignancies is not mentioned nor is the risk due to common cancers such as cancer of the breast, prostate, lung, and colon addressed, although they account for half of all new cancer diagnoses annually [4, 5] . Patients with cancer are a growing group at increased risk of tuberculosis given that almost 40% of North American's will develop cancer in their lifetime, cancer survival is steadily improving, and the number of foreign-born persons from tuberculosis-endemic countries living in low tuberculosisincidence countries is increasing [4, 5] . The risk of tuberculosis reactivation due to immunosuppression from cancer therapies has changed over time and is also different between cancer types. Treatments for hematologic cancer such as combination therapies, purine analogues, targeted monoclonal antibodies, and hematopoietic stem cell transplantation are more deeply immunosuppressive compared to therapies that were available prior to the 1970s, whereas local damage due to radiotherapy in head and neck cancers has decreased with newer radiation modalities [6, 7] .
Targeted screening and treatment of latent tuberculosis infection (LTBI) is an important strategy for groups at high risk of developing active tuberculosis. We conducted a systematic review and metaanalysis of studies that assessed the risk of developing active tuberculosis in cancer patients. These estimates were stratified by important predictors, including cancer type and tuberculosis incidence in the country of study in order to determine which patients would benefit most from LTBI screening and treatment.
guidelines [8, 9] . The following 7 electronic databases were searched from database inception to 1 December 2015: Medline, Medline In-Process, EMBASE, PubMed, the Cochrane Database of Systematic Reviews, Cancerlit, and Web of Science. Search terms combined MESH terms, text words, and exploded terms including "Mycobacterium tuberculosis, " "tuberculosis, " "cancer, " "cancerous, " "neoplasms, " "epidemiological studies, " "seroepidemiology studies, " "risk factors, " "odds ratio, " "prevalence, " "incidence, " "risk, " and "multivariate analysis. " The strategy and search terms for Medline are listed in Appendix Table 1 . The searches were limited to human studies published in English or French. Additional studies were identified by hand-searching references from relevant articles.
Study Selection
We included studies that reported new cases of tuberculosis that occurred concurrently or after the diagnosis of cancer and that provided the number of cancer patients at risk during the study period. A subset of 13 studies also reported the follow-up time of the entire cohort. Neoplasms were diagnosed pathologically and tuberculosis was diagnosed bacteriologically or pathologically and, in a few studies cases, were identified clinically. Studies where isoniazid prophylaxis was provided to the entire study population or certain subgroups were excluded.
Data Extraction and Quality Assessment
Two independent reviewers screened the title and abstract of potentially relevant studies and assessed their eligibility and quality. Data extraction was performed independently by 2 authors who used a standardized data-extraction tool. Discrepancies were resolved at all stages by consensus or with a third author when necessary. Patient characteristics included age, sex, type of malignancy, site of tuberculosis, and diagnostic methods used. Data was stratified by specific cancer type and then grouped as either hematologic or solid malignancies. Studies that included both types of malignancies were classified as mixed, but data was stratified if reported separately. Study characteristics included design type, recruitment methods, site, as well as type and length of follow-up.
Study quality was assessed with a standardized tool based on a modified version of the Newcastle-Ottawa scale [10] , where selection, exposure, detection, and attrition bias were assessed. We did not assess small study effects (eg, publication bias) as this is not reliable for studies of cumulative incidence (proportions) [11] .
Data Synthesis and Analyses
The main outcome was cumulative incidence rate (CIR) of tuberculosis calculated by the number of new tuberculosis cases/number of cancer patients at risk occurring during the study period per 100 000. To explore heterogeneity, the data were stratified by tuberculosis incidence in the study country, cancer type (hematologic and solid and mixed types), and in the pre-and post-1980 time periods. Six studies from the United States accounted for 98% of all cancer cases and were of higher quality. The main metaanalysis was performed on these studies in order to reduce differences due to varying tuberculosis incidence, diagnostic capacity, therapeutic regimens, and access to healthcare within different countries. For all studies the CIRs were transformed with arcsine to minimize the effect of standard error variance and pooled with a random effects model using the metaprop and metagen default commands of the meta package (3.4-1) in R (version 3.1.3) [12, 13] . These estimates were backtransformed, and results were presented as CIR. Arcsine and logarithmic transformations were compared in a sensitivity analysis. Heterogeneity was estimated with I 2 and classified as low, moderate, and high level corresponding to I 2 values of 25%, 50%, and 75%, respectively [14] .
To adjust for risk of prior tuberculosis exposure, incidence rate ratios (IRRs) and 95% confidence intervals were estimated by tuberculosis incidence in cancer patients from each study/ tuberculosis incidence in the general population of the country. Tuberculosis incidence rates (IRs) in the general population were calculated as the mean tuberculosis IRs/year during the study period ± 1 year from the country in which each study was conducted. Annual country-specific tuberculosis IRs were obtained from World Health Organization estimates from 1990 to 2015 or published national reports on tuberculosis incidence for years prior to 1990 [15] . Given that tuberculosis is a reportable disease in most countries and the majority of tuberculosis cases are symptomatic and diagnosed, these data are considered to be the most accurate estimates of tuberculosis in the general population. Tuberculosis incidence in study countries were defined as high incidence >100/100 000, intermediate 30-100/100 000, or low <30/100 000 [16] . This category was assigned to studies based on reported tuberculosis incidence after 1980 as the United States had tuberculosis incidence rates >30/100 000 in the years prior to 1980. Studies were stratified into pre-and post-1980s because tuberculosis rates in the United States were much higher before (up to 90/100 000) compared to after the 1980s (<12/100 000) and because there was 1 large study from both Sloan Kettering [17, 18] and MD Anderson [19, 20] before and after the 1980s.
A sensitivity analysis of a subset of 13 of the 23 studies that had included person-time of follow-up to determine the risk of tuberculosis over time after diagnosis. Tuberculosis IR per 100 000 persons/year during study follow-up among cancer patients was calculated by the number of incident tuberculosis cases/mean follow-up × N. For studies that reported a median and/or range of follow-up, the median was used to estimate follow-up time.
RESULTS

Included Studies
Electronic database and hand searching yielded 6843 unique articles. After screening titles and abstracts, the full texts of 260 articles were reviewed (Appendix Figure 1) . A total of 23 studies reporting 593 tuberculosis cases occurring in 324 041 cancer patients over 7 decades were included. The CIRs of tuberculosis in these studies, stratified by tuberculosis incidence in study country and cancer type, were described (Table 1 and Table 2 Tuberculosis incidence was defined as high if >100/100 000, as intermediate if 30-100/100 000, and as low if <30/100 000 after 1980 [16] . Confidence intervals (CIs) for population incidence rate were calculated using the formula: log(IR) ± (1.96*√1/tuberculosis cases), where IR is mean of IRs during study duration ±1 year and tuberculosis cases where mean of cases during study duration ±1 year. CIs for cumulative incidence rates were calculated using the Clopper-Pearson method ("exact" binomial interval). CIs for cancer subtypes are shown in forest plots (Appendix Figures 3, 4 , and 5). Abbreviations: CI, confidence interval; CIR, cumulative incidence rate; HSCT, hematopoietic stem cell transplantation; IR, incidence rate; IRR, incidence rate ratio. Acute leukemia included patients with acutely lymphoblastic leukemia (n = 45) and acute nonlymphoblastic leukemia (n = 44). Tuberculosis was found in 2 patients, 1 in each type of leukemia. The total number of patients in this study was 213; however, we removed 25 bone marrow transplant (BMT) for noncancer hematologic malignancies, thus 188 patients with a hematologic malignancies were included.
e Age is reported as median (years) unless indicated as mean. The total number of patients in this study was stated as 130; however, 2 patients (both with tuberculosis) were removed from our calculations since tuberculosis was diagnosed before cancer diagnosis.
g
The annual cumulative incidence reported in the study was of 9135/100 000.
h
The authors estimated the population rate to be 360/100 000 and a standardized morbidity ratio of 11.5 for tuberculosis in children with cancer (or incidence of tuberculosis 4150/100 000 in children with cancer).
i Calculated only for cancers for which the total number of cancer cases was available. The total number of patients in this study was stated as 90 022; however, only 10 033 patients with a particular cancer were described. Since no additional information was given for the other 79 989 cases, we used 10 033 in our calculation of total cumulative incidence. Tuberculosis incidence was defined as high if >100/100 000, as intermediate if 30-100/100 000, and as low if <30/100 000 after 1980 [16] .
Abbreviations: CI, confidence interval; CIR, cumulative incidence rate; IRR, incidence rate ratio. a Confidence interval for I 2 could not be estimated for fewer than 3 studies [14] .
Appendix Figure 2 ) . Cancer patients from 6 US studies accounted for 98% of all cancer patients at risk (n = 317 243) [17-20, 24, 27] . Metaanalyses of these studies, overall and stratified by cancer type and study period, are reported in Table 2 and in Appendix Figures 3 and 4 .
The study quality of all 23 identified studies and the 4 types of bias are summarized in Table 3 and detailed in Appendix Table 2 . The overall quality of the data was judged to be low to moderate because all studies recruited patients from a single center and there was moderate to high detection bias in one third of studies (7/23) given that cases were detected clinically (response to tuberculosis treatment) in 3 studies, and there was no description of how tuberculosis cases were diagnosed in another 4 studies . The quality of the 6 US studies was better and was estimated to be moderate. The body of data from the person-time studies (n = 13) was judged to be low due to moderate to high detection bias in half the studies and serious imprecision due to small study size and very low numbers of tuberculosis cases [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] .
Tuberculosis Cumulative Incidence
In all 23 studies, the CIR of tuberculosis in patients with hematologic malignancies reflected the incidence in the country of origin, which was highest in high tuberculosis-incidence countries (6873/100 000 population) and lower in intermediateand low-incidence countries (2686 and 418/100 000 population, respectively). There was a similar decreasing gradient of tuberculosis incidence by country tuberculosis incidence for solid cancers (Table 2) . Despite stratification by cancer type, tuberculosis incidence in study country and study period among the 23 studies, there was a residual high level of heterogeneity.
In the metaanalysis of the 6 US studies, CIR decreased significantly and by 3-fold for hematologic cancers pre-and post-1980 (728 vs 219/100 000 population) but the IRR remained similar (21 vs 26; Table 2 , Appendix Figures 3 and 4) . Rates in acute leukemia did not change over the study period, whereas rates decreased among those with lymphoma (Table 2, Figure 1 ). The CIR for solid cancers decreased by more than 6-fold over the study period from 413 to 64/100 000 in the pre-vs post-1980 studies (Table 2, Figure 2 ). The IRR decreased from 19 to 7 over this time period, with an overall estimate of 12.8. The greatest decrease in rates occurred in those with head and neck cancers (884 to 143/100 000) and lung cancer (645 to 83/100 000; Table 2, Figure 2 ). Head and neck and lung cancers had an IRR of 16 and 9 compared to the general population, respectively, post-1980. Incidence rates of breast and other tumors after 1980 were much lower, with a CIR of 41/100 000 and an IRR High: Recruited in a highly specialized setting that will not include all eligible cancer patients.
Exposure Bias: Low: Subjects had a pathological diagnosis of cancer. High: Subjects had a clinical diagnosis of cancer or had an unclear or unspecified method of diagnosis for their cancer.
Detection Bias: Low: Subjects tested had a bacteriological or pathological diagnosis of TB. Moderate: Some subjects had a clinical diagnosis of TB.
High: There was no mention of how TB cases were diagnosed.
Attrition Bias: Low: All subjects were followed up. Moderate: Only study duration was reported.
of 5. After 1980, hematologic cancer patients had the highest rate of active tuberculosis, with a CIR/100 000 of 219 and an IRR of 26 followed by head and neck (143 vs 16), lung (83 vs 9), and breast and other solids cancers (40 vs4 ). There was high residual heterogeneity across all estimates for cumulative incidence despite stratification by cancer subtype and year of study (Table 2) .
Sensitivity Analysis
The descriptive characteristics of the 13 studies that reported on median or mean follow-up time are listed in Table 1  [ [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . A total of 65 cases of tuberculosis were identified in 4499 cancer patients from 11 countries and spanned 4 decades (1975-2013) (Appendix Table 3 and Figure 5 ). Included studies were small, with a mean of 285 study participants (range, 18-1809) and a mean of 5 tuberculosis cases (range, 1-19) ( Table 1) . Median length of follow-up ranged from 26 to 122 months (median of medians = 46 months). The majority of studies reported on hematologic malignancies [27, 31, 38] . The tuberculosis incidence was higher in high tuberculosis-incidence countries and higher in hematologic vs solid tumors, consistent with results from the cumulative incidence studies (Appendix Table 3 ). The annual tuberculosis incidence per year after cancer diagnosis could not be estimated from the data, thus the time to tuberculosis diagnosis after cancer diagnosis and the time period at greatest risk could not be estimated.
DISCUSSION
This metaanalysis in the 6 US studies showed that rates of active tuberculosis decreased significantly among all cancer types over the 6-decade study period in a low tuberculosis-incidence setting. Hematologic cancer patients had the highest rates of active tuberculosis, followed by head and neck cancers, lung cancer, and breast cancer patients. Our study results support the contention that all types of cancer increase the risk of the development of active tuberculosis, but with varying degrees. This is likely due to both intrinsic immunosuppression due to the cancer itself, the immunosuppressive effects of chemotherapy, or other host factors that may increase the susceptibility to both cancer and tuberculosis. Although the rate of tuberculosis in patients with hematologic malignancy decreased over the study period, the relative risk compared to the US general population remained high. The magnitude of active tuberculosis risk supports the importance of targeted LTBI therapy for this group with a lower threshold of tuberculin skin testing (TST) of 5 mm. In the review of all studies the risk of developing active tuberculosis in those with hematologic malignancies was highest in high tuberculosisincidence countries, which is likely due to the risk of recent Figure 1 . Cumulative tuberculosis incidence rates stratified by hematologic cancer type in the US population over time . Symbols represent the cumulative incidence rate for each study per 100 000. The studies' periods were centered; arrows show the beginning and end of each study inclusion period. The dashed line represents the US tuberculosis incidence rate per 100 000 population. The studies included are Kamboj et al 2006 [18] , Kaplan et al 1974 [17] , and Libshitz et al 1997 [20] .
infection as well as latent tuberculosis reactivation during immune suppression in this setting.
The incidence of active tuberculosis in patients with head and neck cancers (HNSCC) decreased by more than 6-fold over the study period in the United States, while the relative risk decreased but remained very high. The increased tuberculosis risk in these patients may be confounded by the association of heavy smoking and drinking as they are independent risk factors for developing active tuberculosis. It is unclear if risk of HNSCC is principally through the direct impairment of antituberculosis immunity by cigarette smoking or alcohol consumption or the association of these risk factors with poverty, malnutrition, and low socioeconomic status (SES). The dramatic decrease in incidence of tuberculosis in those with head and neck cancers in the pre-and post-1980 period may be due to decreasing tuberculosis rates, as well as the change in etiology of head and neck cancers associated risk factors and treatment modalities. Non-human papillomavirus (HPV)-associated HNSCC typically occurs in low-to middle-class males who are heavy smokers and drinkers, whereas HPV-associated HNSCC occurs in young nonsmoking males of high SES. Between 1998 and 2004, the incidence of HPV-positive HNSCC in the United States increased by 225%, whereas HPV-negative cancers decreased by 50% [40] . Treatment modalities for head and neck cancer evolved from using intensive radiotherapeutic regimens to directed beam therapy over the study period [7] . Improved supportive care over the study period led to decreased risk of severe malnutrition, which is another known risk factor for tuberculosis reactivation and may be another factor leading to decreased HNSCC rates.
The incidence of tuberculosis in lung cancer patients decreased dramatically over the study period in the United States, with the relative risk decreasing but remaining high after 1980. The increased risk of tuberculosis in those with lung cancer may be due to local immunologic effect of the cancer but also to confounders such as heavy cigarette smoking and alcohol consumption. We do not have an explanation for the dramatic decreased risk of tuberculosis in lung cancer patients over the study period other than lower exposure to active tuberculosis after 1980. Active tuberculosis occurred concurrently or soon after the cancer diagnosis in more than half of the patients with head and neck and lung cancer in 2 large studies included in our metaanalysis [17, 20] . This highlights the importance of screening these patients for active tuberculosis at diagnosis and, if absent, to screen and treat for LTBI.
In our metaanalysis, breast cancer and other solid tumors had a risk of developing active tuberculosis of 41/100 000 and an IRR of 5 compared to the US population. Although the risk is not as high as for hematologic, head and neck, and lung cancers, the number of patients at risk is very large. In the Kamboj et al study, the risk of developing active tuberculosis in the United States compared to the foreign-born population was 25 vs 100/100 000 population [18] . Based on this finding, the authors recommended that the US-born population with solid tumors other than head and neck cancers should not be screened for LTBI due, in part, to the associated risk of hepatotoxicity with LTBI therapy. While the mean age of developing solid cancer is between 50 and 60 years, the emergence of shorter-course rifampin-based therapies without age-related hepatotoxicity may justify LTBI screening and therapy for foreign-born populations with solid cancers.
The strength of our systematic review and metaanalysis is that it included a large number of cancer patients over 6 decades and there was sufficient detail to stratify the results by cancer type. The majority of patients in the included studies (98%) were from the United States, which reduced heterogeneity. The results of this study should be generalizable to other low tuberculosis-incidence settings with a moderate level of migration. One important limitation of our study is that follow-up time was not reported in most studies and we were unable to estimate the annual risk of developing active tuberculosis after cancer diagnosis or to estimate the time period at greatest risk for developing active tuberculosis. Some studies spanned 25 years during which tuberculosis rates decreased and cancer therapies evolved, but we were not able to estimate the risk of tuberculosis by decade. There was potential differential tuberculosis case detection bias between those with and without cancer. Case detection may have been higher among cancer patients as a result of closer monitoring and lower in the general population due to missed undiagnosed cases who died or self-healed. We were unable to stratify for important variables, as there is limited data available on TST status, country of birth, and underlying co-morbidities including smoking, alcohol, and human immunodeficiency virus status.
CONCLUSIONS
Our study results highlight the increased risk of active tuberculosis in all patients with cancer. Those with hematologic malignancies and head and neck are at the highest risk and should be targeted for LTBI screening and treatment as per published guidelines [2, 3] . Other groups to consider for screening for LTBI and treatment are all lung cancer patients as they are at high risk and the foreign born population with breast and other cancers as they have a moderate increased risk of developing active tuberculosis.
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